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Abstract
Background: Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as
a novel etiologic agent of viral pneumonia. We aimed to compare clinical features of 165 Italian patients with
laboratory confirmed or unconfirmed 2019-nCoV pneumonia.
Methods: On March 31, 2020, hospitalized patients who presented with fever and/or respiratory symptoms,
exposures, and presence of lung imaging features consistent with 2019-nCoV pneumonia were included. Before
admission to a hospital ward, patients underwent RT-PCR based SARS-CoV-2 RNA detection in their nasopharyngeal
swab samples.
Results: Of 165 patients studied, 119 had positive RT-PCR results and 46 were RT-PCR negative for 2 days or longer (i.e.,
when the last swab sample was obtained). The median age was 70 years (IQR, 58–78), and 123 (74.6%) of 165 patients had
at least one comorbidity. The majority of patients (101/165, 61.2%) had a mild pneumonia, and the remaining patients (64/
165, 38.8%) a severe/critical pneumonia. We did not find any substantial difference in symptoms, incubation periods, and
radiographic/CT abnormalities as well as in many of the biological abnormalities recorded. However, at multivariable analysis,
higher concentrations of hemoglobin (OR, 1.34; 95% CI, 1.11–1.65; P= 0.003) and lower counts of leukocytes (OR, 0.81; 95%
CI, 0.72–0.90; P< 0.001) were statistically associated with confirmed COVID-19 diagnosis. While mortality rates were similar,
patients with confirmed diagnosis were more likely to receive antivirals (95% vs 19.6%, P< 0.001) and to develop ARDS (63%
vs 37%, P = 0.003) than those with unconfirmed COVID-19 diagnosis.
Conclusions: Our findings suggest that unconfirmed 2019-nCoV pneumonia cases may be actually COVID-19 cases and that
clinicians should be cautious when managing patients with presentations compatible with COVID-19.
Keywords: Pneumonia, COVID-19, Clinical and laboratory findings, Outcomes
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: maurizio.sanguinetti@unicatt.it
†Giulia De Angelis and Brunella Posteraro contributed equally to this work.
1Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e
Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy
2Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione
Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Rome,
Italy
Full list of author information is available at the end of the article
De Angelis et al. BMC Infectious Diseases          (2020) 20:775 
https://doi.org/10.1186/s12879-020-05504-7
Background
The 2019 novel coronavirus (2019-nCoV), named severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), became notorious since December 2019 as a new
etiologic agent of viral pneumonia [1]. In early illness
stages, patients with coronavirus disease 2019 (COVID-
19) present with symptoms of acute respiratory infec-
tion, which can progress to acute respiratory distress
syndrome (ARDS) and other serious complications [2].
Because of substantial pneumonia-related morbidity and
mortality [3], testing for SARS-CoV-2 infection of pa-
tients who meet the suspected-case definition for
COVID-19 [4] is central for their management. Accord-
ingly, provision of supportive care (e.g., oxygenation,
ventilation, and fluid therapy) and/or administration of
antiviral agents may be decisive [5].
Real-time reverse-transcriptase–polymerase-chain-reac-
tion (RT-PCR) based SARS-CoV-2 RNA detection in re-
spiratory samples (e.g., nasopharyngeal swabs) is the
reference diagnostic method to confirm COVID-19 [6].
However, one or more negative results do not exclude the
likelihood of SARS-CoV-2 infection [4]. Currently pub-
lished studies suggest lung imaging, biomarkers, and other
non-microbiological tests as ancillary diagnostic methods
[6], encouraging further investigation to understand the
value of radiological or laboratory findings to diagnose
COVID-19. We comparatively explored the clinical fea-
tures of 165 patients with laboratory confirmed or uncon-
firmed 2019-nCoV pneumonia admitted to COVID-19
wards of the Fondazione Policlinico A. Gemelli IRCCS,
which is a tertiary care university hospital in Rome, Italy.
Thus, we investigated the prospect that cases with a nega-
tive RT-PCR test result are actually cases of 2019-nCoV
pneumonia or, in other words, are not to distinguish from
those without confirmation test performed.
Methods
This retrospective, single-center observational study was
conducted in accordance with the Declaration of
Helsinki and was approved by the Ethics Committee of
the Fondazione Policlinico A. Gemelli IRCCS (reference
number 17057/20), and written informed consent was
obtained from each enrolled patient. All patients who
were hospitalized for suspected 2019-nCoV pneumonia
[7] on March 31, 2020 were considered for recruitment.
Inclusion criteria were fever and/or respiratory symp-
toms, exposures, and presence of lung imaging features
consistent with 2019-nCoV pneumonia [8]. At the emer-
gency room (before admission to a hospital ward), all pa-
tients had undergone nasal and oropharyngeal swabs for
detection of one or more SARS-CoV-2 specific nucleic
acid targets [9], using the Korean Ministry of Food and
Drug Safety approved Allplex 2019-nCoV assay (Arrow
Diagnostics S.r.l., Genova, Italy). Samples resulted
negative had been repeated after 48–72 h. To rule out
the presence of infections due to common viral (adeno-
virus, coronaviruses 229E, HKU1, NL63, OC43, influ-
enza viruses, rhinovirus/enterovirus, etc.) or bacterial
(Bordetella pertussis, Chlamydophila pneumoniae, Le-
gionella pneumophila, Mycoplasma pneumoniae) patho-
gens, patients’ samples had also been tested with the
GenMark’s ePlex Respiratory Pathogen Panel assay.
Eleven patients yielding positive results for the etio-
logical agents above mentioned were not included.
We retrieved demographic, clinical, laboratory, im-
aging, treatment, and outcome data from the patients’
medical chart records. We classified cases as mild (see
above specification), severe (i.e., dyspnea, respiratory
rate ≥ 30 breaths/min, blood oxygen saturation ≤ 93%,
and partial pressure of arterial oxygen [PaO2]/fraction of
inspired oxygen [FiO2] ≤300 mmHg), or critical (i.e., re-
spiratory failure, septic shock, and/or multiple organ fail-
ure) pneumonia. We recorded chest X-ray or computed
tomography (CT) features using the Fleischner Society
terminology [10], we defined ARDS based on timing,
lung imaging, origin of edema, and oxygenation as speci-
fied in the Berlin definition [11], and we defined liver in-
jury as transaminase elevation two- to three-times the
upper limit of normal (e.g., 45 U/L for alanine amino-
transferase). According to the Italian Society of Infec-
tious Diseases guidelines for COVID-19 treatment [12],
we administered antiviral agents (e.g., lopinavir/ritona-
vir) to all patients with severe/critical disease or to pa-
tients with mild disease who had comorbidities
including age > 70. Categorical variables were expressed
as number with percentage and were compared using
the χ2 test, and continuous variables were expressed as
median with interquartile range (IQR) and were com-
pared using the Mann-Whitney U-test. A two-sided P
value of < 0.05 was considered statistically significant.
We performed univariate analysis using the aforemen-
tioned tests, and all significant variables (among demo-
graphics and baseline characteristics) were included in a
multivariable logistic regression model to identify those
variables that were statistically associated with confirmed
COVID-19 diagnosis. Odds ratio (OR) values with 95%
confidence intervals (CIs) were calculated. All analyses
were performed with Stata software version 11.1 (Stata-
Corp, College Station, TX, USA).
Results
On March 31, 2020, 176 patients were hospitalized at
our center with a suspicion of 2019-nCoV pneumonia,
and 165 patients were finally included. Of them, 119
were confirmed COVID-19 cases based on positive RT-
PCR results on nasopharyngeal swabs [4], and 46 were
RT-PCR negative for 2 days or longer (i.e., when the last
swab sample was obtained).
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Table 1 shows demographic and clinical characteristics
of 165 patients at baseline. The median age was 70 years
(IQR, 58–78), and 113 patients were males. One hundred
and twenty-three (74.6%) patients had at least one comor-
bidity. The most common symptoms at admission were
fever (n = 155, 93.9%), dyspnea (n = 92, 55.8%) and cough
(n = 77, 46.7%), and the median time from symptom onset
to COVID-19 diagnosis was 7 days (IQR, 3–10). Overall,
lactate dehydrogenase levels (median value, 289U/L; IQR,
230–415) and C-reactive protein levels (median value, 74.0
mg/L; IQR, 32.2–139.4) were elevated. One hundred and
twenty-seven patients (77%) presented with X-ray signs of
ground-glass opacity, and 106 (64.2%) with signs of consoli-
dation. At admission, 101 (61.2%) presented with a mild
pneumonia, and the remaining 64 patients (38.8%) with a
severe/critical pneumonia.
Treatments and outcomes of 165 patients are detailed
in Table 1. Overall, 92 patients (55.8%) developed ARDS,
and 14 of them (8.5%) septic shock, which needed trans-
fer to ICU. Most patients (n = 128, 77.6%) were treated
with oxygen support, antivirals (n = 122, 73.9%), and an-
tibiotics (n = 133, 80.6%). Forty-six patients (27.9%) re-
ceived therapy with interleukin-6 receptor inhibitors.
Overall, 16 (9.7%) of 165 patients died at the follow-up
end (n = 13 because ARDS, n = 2 because of septic shock,
n = 1 because of multiple comorbidities).
At univariate analysis, fever was significantly more fre-
quent in patients with confirmed diagnosis (96.6% vs
87.0%, P = 0.02). This group presented also with signifi-
cantly lower levels of leucocytes (median value, 6.0 ×
109/L vs 10.1 × 109/L; P < 0.001), neutrophils (median
value, 4.6 × 109/L vs 7.7 × 109/L; P < 0.001), platelets
(median value, 203 × 109/L vs 250 × 109/L; P = 0.01), and
procalcitonin (median value, 0.08 ng/mL vs 0.15 ng/mL,
P = 0.006), and higher levels of hemoglobin (median
value, 14.1 g/dL vs 12.1 g/dL; P < 0.001), alanine amino-
transferase (median value, 26 U/L vs 19 U/L, P = 0.02),
and lactate dehydrogenase (median value, 316 U/L vs
245 U/L; P < 0.001). Patients with confirmed diagnosis
were also more likely to receive antivirals (95% vs 19.6%,
P < 0.001) and to develop ARDS (63% vs 37%, P = 0.003)
than those without confirmed diagnosis. There were no
other significant differences between the two groups.
At multivariable analysis, higher concentrations of
hemoglobin (OR, 1.34; 95% CI, 1.11–1.65; P = 0.003) and
lower counts of leukocytes (OR, 0.81; 95% CI, 0.72–0.90;
P < 0.001) were found to be statistically associated with
confirmed diagnosis in the overall cohort.
Discussion
We tested the hypothesis that negative patients did not
differ from SARS-CoV-2 RNA positive patients by com-
paring features of 165 cases with clinically diagnosed
2019-nCoV pneumonia in our hospital. We did not find
any substantial difference in symptoms, incubation pe-
riods, and radiographic/CT abnormalities as well as in
many of the biological abnormalities recorded. However,
blood/serum test results showed that patients with
laboratory-confirmed diagnosis of 2019-nCoV pneumo-
nia were more likely to have higher levels of hemoglobin
and lower levels of leukocytes. Additionally, the propor-
tion of ARDS in the group of COVID-19 confirmed pa-
tients was significantly higher than in the group of
COVID-19 unconfirmed patients.
Large or small descriptive studies published in 2020
mainly focused on patients with laboratory-confirmed
2019-nCoV pneumonia [2, 13, 14]. Nonetheless, among
72,314 cases (as of February 11, 2020) from the COVID-
19 outbreak in China, 16,186 (22%) and 10,567 (15%) of
them could not receive laboratory confirmation for
COVID-19 and, then, were classified as suspected cases
or clinically diagnosed cases, respectively [8]. Although
testing for SARS-CoV-2 in our laboratory was not re-
stricted [15], 46 (27.8%) of 165 patients with 2019-nCoV
pneumonia did not have a laboratory-confirmed diagno-
sis in our study. Despite a well-documented active virus
replication in the upper respiratory tract [16], swab sam-
ples may have a limited sensitivity to identify cases. Sam-
pling or testing related factors may be responsible for
false-negative RT-PCR results, necessitating additional
sample collection from the lower respiratory tract speci-
mens including sputum [4].
It is plausible that our SARS-CoV-2 negative patients
were outside the window of peak shedding in the upper
respiratory tract samples or did not have symptoms highly
suggestive for upper respiratory tract infection [16]. Ac-
cordingly, eight of 119 patients with positive RT-PCR re-
sults became positive only with swabs taken on
subsequent days after the first (negative) sampled swab,
and their median time from symptom onset did not differ
from that of 111 remaining patients (7 days vs 7 days, P =
0.76). Furthermore, the sensitivity of the Allplex 2019-
nCoV assay might have limited by its requirement that
three genes were all detectable for a positive result. In our
study, all 46 patients had a radiological evidence of pneu-
monia not attributed to any typical respiratory viral infec-
tion agents, including the human coronaviruses HKU1,
OC43, NL63, 229E, the influenza virus A and B, and
others (data not shown). It is worthy to note that the find-
ing of typical ground glass opacities in chest CTs of clinic-
ally diagnosed patients [17] prompted the Chinese
authorities, at one point in early February 2020, to count
these patients as confirmed cases [18]. This allowed iden-
tifying and quarantining patients as early as possible.
In conclusion, using the clinical diagnosis as the
reference standard, the RT-PCR testing allowed to
correctly identify two thirds of our patients as
COVID-19 while one third was not correctly
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Age (years), median (IQR) 70 (58–78) 68 (58–77) 73.5 (58–85) 0.09 …
Male sex 113 (68.5) 85 (71.4) 28 (60.9) 0.19 …
Pre-existing conditions
Any 123 (74.6) 86 (72.3) 37 (80.4) 0.28 …
Cardiovascular disease 77 (46.7) 59 (49.6) 18 (39.1) 0.23 …
Connective tissue disease 30 (18.2) 23 (19.3) 7 (15.2) 0.54 …
Nervous system disease 29 (17.6) 18 (15.1) 11 (23.9) 0.18 …
Diabetes 22 (13.3) 15 (12.6) 7 (15.2) 0.66 …
Malignancy 21 (12.7) 12 (10.1) 9 (19.6) 0.10 …
Respiratory system disease 18 (10.9) 12 (10.1) 6 (13.0) 0.59 …
Chronic kidney disease 15 (9.1) 8 (6.7) 7 (15.2) 0.09 …
Immunodeficiency 7 (4.2) 3 (2.5) 4 (8.7) 0.08 …
Chronic liver disease 3 (1.8) 3 (2.5) 0 (0.0) 0.28 …
Otherc 29 (17.6) 17 (14.3) 12 (26.1) 0.07 …
Symptoms at admission
Fever 155 (93.9) 115 (96.6) 40 (87.0) 0.02 …
Shortness of breath (or dyspnea) 92 (55.8) 63 (52.9) 29 (63.0) 0.24 …
Cough 77 (46.7) 60 (50.4) 17 (37.0) 0.12 …
Diarrhea/Nausea/Vomiting 6 (3.6) 3 (2.5) 3 (6.5) 0.22 …
Days from symptom onset, median (IQR) 7 (3–10) 7 (3–10) 7 (3–10) 0.41 …
Signs at admission, median (IQR)
Heart rate (beats/min) 89 (80–101) 89 (80–102) 92 (80–100) 0.99 …
Respiration rate (breaths/min) 14 (12–15) 14 (12–16) 13 (12–15) 0.24 …
Blood oxygen saturation (%) 94 (90–96) 94 (90–96) 93 (90–97) 0.74 …
Systolic blood pressure (mmHg) 130 (120–
140)
130 (120–140) 130 (118–140) 0.97 …
Diastolic blood pressure (mmHg) 80 (70–86) 80 (70–86) 75 (66–88) 0.56 …
qSOFA score (≥2) 25 (15.2) 17 (14.3) 8 (17.4) 0.62 …
Chest X-ray/CT findings
Ground-glass opacity (GGO) 127 (77.0) 96 (80.7) 31 (67.4) 0.07 …
Consolidation 106 (64.2) 79 (66.4) 27 (58.7) 0.35 …
Pleural effusion 40 (24.2) 24 (20.2) 16 (34.8) 0.19 …
CT findings onlyd
GGO and reticular 29/112
(17.6)
21/76 (17.6) 8/36 (17.4) 0.54 …
Pleural thickening/retraction 6/112 (3.6) 3/76 (2.5) 3/36 (6.5) 0.34 …
Fibrotic steaks 5/112 (3.0) 3/76 (2.5) 2/36 (4.3) 0.70 …
Air bronchogram 3/112 (1.8) 2/76 (1.7) 1/36 (2.2) 0.96 …
Bronchus distortion 2/112 (1.2) 2/76 (1.7) 0/36 (0.0) 0.33 …
Spectrum of disease
Mild 101 (61.2) 72 (60.5) 29 (63.0) 0.76 …
Severe 53 (32.1) 39 (32.8) 14 (30.4) 0.77 …
Critical 11 (6.7) 8 (6.7) 3 (6.5) 0.96 …
Blood parameters, median (IQR)
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Leucocytes (×109/L; normal range 4.0–10.0) 6.4 (4.8–9.7) 6.0 (4.7–8.1) 10.1 (6.1–15.4) < 0.001 0.81 (0.72–0.90)
Neutrophils (×109/L; normal range 2.0–7.0) 4.9 (3.5–7.7) 4.6 (3.3–6.3) 7.7 (4.6–11.7) < 0.001 …
Lymphocytes
(×109/L; normal range 1.0–3.0)
1.1 (0.8–1.4) 1.1 (0.8–1.4) 1.2 (0.7–1.6) 0.78 …
Neutrophils (%) 77.1
(69.5–82.8)
76.3 (67.6–82.4) 80.1 (71.9–87.3) 0.03 …
Lymphocytes (%) 15.8
(10.5–23.4)
17.6 (12.5–24.3) 12.1 (7.6–20.4) 0.003 …
Platelets (×109/L; normal range 150–450) 210
(169–264)
203 (165–252) 250 (189–301) 0.01 …
Hemoglobin (g/dL; normal range 13–17) 13.8
(12.1–14.9)
14.1 (13.0–15.1) 12.1 (10.6–14.1) < 0.001 1.34 (1.11–1.65)
Serum parameters, median (IQR)
Alanine aminotransferase (U/L; normal range
7–45)
24 (16–39) 26 (17–40) 19 (13–33) 0.02 …
Lactate dehydrogenase
(U/L; normal range 120–250)
289
(230–415)
316 (254–433) 245 (195–336) < 0.001 1.00 (0.99–1.01)
Creatinine (mg/dL; normal range: 0.7–1.1) 0.9 (0.8–1.3) 0.9 (0.8–1.3) 1.0 (0.8–1.3) 0.59 …
Creatine kinase (U/L; normal range 30–170) 120
(66–219)
122 (72–218) 107 (51–219) 0.36 …
Urea (mg/dL; normal range 10–23) 17 (14–26) 17 (13–25) 19 (15–32) 0.32 …
Infection-related biomarkers, median (IQR)
Procalcitonin (ng/mL; normal range 0–0.5) 0.09
(0.04–0.18)
0.08 (0.04–0.15) 0.15 (0.07–0.63) 0.006 …
C-reactive protein
(mg/L; normal range 0–5.0)
74.0
(32.2–139.4)
66.9 (33.6–130.5) 93.6 (22.1–163.9) 0.59 …
Complications
Acute respiratory distress syndrome 92 (55.8) 75 (63.0) 17 (37.0) 0.003 …e
Liver injury 47 (28.5) 38 (31.9) 9 (19.6) 0.11 …e
Septic shock 14 (8.5) 7 (5.9) 7 (15.2) 0.06 …e
Admission to intensive care unit 14 (8.5) 12 (10.1) 2 (4.4) 0.23 …e
Treatment
Oxygen support (nasal cannula) 128 (77.6) 98 (82.4) 30 (65.2) 0.02 …e
Antiviral therapy 122 (73.9) 113 (95.0) 9 (19.6) < 0.001 …e
Antibiotic therapy 133 (80.6) 93 (78.2) 40 (87.0) 0.20 …e
Interleukin-6 receptor inhibitor therapy 46 (27.9) 45 (37.8) 1 (2.2) < 0.001 …e
Outcome
Discharged 125 (75.8) 88 (74.0) 37 (80.4) 0.38 …e
Still in hospital as of 4/23/2020f 24 (14.6) 20 (16.8) 4 (8.7) 0.18 …e
Died 16 (9.7) 11 (9.2) 5 (10.9) 0.75 …e
Data are no. (%) unless specified otherwise. Denominators indicate data lacking for 53 patients. Abbreviations: OR, Odds ratio; CI, confidence interval; IQR,
interquartile range; qSOFA, quick sepsis-related organ failure assessment; CT, computed tomography
aLaboratory-based confirmation of 2019-nCoV pneumonia was done by SARS-CoV-2 RNA detection using a well-established RT-PCR assay [9]
bAccording to multivariable logistic regression model analysis (see text for details)
cIncludes anemia, endocrine disorders, inflammatory bowel disease, and obesity
dCT findings in all 112 patients were assessed according to imaging features described elsewhere [10]
eNot calculated because the relative variable was not entered into multivariable logistic regression model (see text for details)
fPatients were admitted between 3/6/2020 and 3/31/2020, with follow-up through 4/23/2020
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identified. However, as undocumented SARS-CoV-2
infections may be a relevant source of transmission
among hospitalized patients [19], we believe that cli-
nicians should exceed on the side of caution when
managing patients with presentations compatible with
COVID-19.
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